The research program in Hematopoietic Cell Transplantation and Immune Reconstitution (Program 08) focuses on elucidating basic biological principles of hematopoietic cell transplantation (HCT) and furthering the treatment of patients with life-threatening hematologic malignancies. The major theme of the Program is the discovery of immunology and stem cell biology principles that can be translated into innovative HCT based therapies. Our goals are: ? To gain fundamental insights into the cellular basis of hematopoietic stem and progenitor cell engraftment. ? To explore the basic biology of graft-versus-host disease (GVHD) and graft-versus-tumor (GVT) reactions in the context of transplantation. ? To develop strategies to improve immune reconstitution. ? To translate promising concepts developed in pre-clinical studies to the clinic. Using a highly interactive group of investigators with a rich array of animal models incorporating the latest techniques of cell biology, imaging, genetics and array technologies we will explore in animal models and in patients the biological principles that govern these immune-based reactions and develop strategies to improve outcomes for our patients. These concepts could also have an impact on a variety of other clinical situations, such as for the treatment of autoimmune disorders and induction of solid organ transplantation tolerance. Using the principles of translational science whereby model systems are developed in the laboratory and concepts are tested in the clinic in a bi-directional fashion, analyzing patients'samples will allow us to test important concepts of HCT and follow critical leads established in research laboratories to the treatment of patients with hematologic disorders.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-06
Application #
8375593
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
6
Fiscal Year
2012
Total Cost
$15,065
Indirect Cost
$4
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Lee, Bee L; Fan, Shenghua K; Lu, Ying (2017) A curve-free Bayesian decision-theoretic design for two-agent Phase I trials. J Biopharm Stat 27:34-43
Mohanty, Suchismita; Chen, Zixin; Li, Kai et al. (2017) A Novel Theranostic Strategy for MMP-14-Expressing Glioblastomas Impacts Survival. Mol Cancer Ther 16:1909-1921
Alcántara-Hernández, Marcela; Leylek, Rebecca; Wagar, Lisa E et al. (2017) High-Dimensional Phenotypic Mapping of Human Dendritic Cells Reveals Interindividual Variation and Tissue Specialization. Immunity 47:1037-1050.e6
Chao, Mark P; Gentles, Andrew J; Chatterjee, Susmita et al. (2017) Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell 20:329-344.e7
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2017) A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods 14:737-742
Sun, Ruping; Hu, Zheng; Sottoriva, Andrea et al. (2017) Between-region genetic divergence reflects the mode and tempo of tumor evolution. Nat Genet 49:1015-1024
Jin, Yuxue; Lai, Tze Leung (2017) A new approach to regression analysis of censored competing-risks data. Lifetime Data Anal 23:605-625
Clarke, Christina A; Glaser, Sally L; Leung, Rita et al. (2017) Prevalence and characteristics of cancer patients receiving care from single vs. multiple institutions. Cancer Epidemiol 46:27-33
Han, Summer S; Ten Haaf, Kevin; Hazelton, William D et al. (2017) The impact of overdiagnosis on the selection of efficient lung cancer screening strategies. Int J Cancer 140:2436-2443
Wender, Paul A; Hardman, Clayton T; Ho, Stephen et al. (2017) Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV. Science 358:218-223

Showing the most recent 10 out of 227 publications